Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

November 11, 2025

Study Completion Date

November 11, 2025

Conditions

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Interventions

DRUG

Larotrectinib Sulfate

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER